Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy. - Université de Bourgogne Accéder directement au contenu
Article Dans Une Revue OncoImmunology Année : 2016

Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy.

Résumé

It is well established that the anticancer immune response determines the success of anthracycline-based adjuvant chemotherapy of breast cancer. This effect is in part due to the capacity of anthracyclines to induce immunogenic cell death (ICD), a cell death modality that is preceded by autophagy and followed by HMGB1 release. Recent data on 1,798 mammary carcinoma specimens indicate that patients harboring neoplastic cells that lack immunohistochemical signs of autophagy or that have lost HMGB1 expression have indeed a poor prognosis.

Domaines

Cancer Immunologie

Dates et versions

hal-01448304 , version 1 (27-01-2017)

Identifiants

Citer

Sylvain Ladoire, David Enot, Fabrice Andre, Laurence Zitvogel, Guido Kroemer. Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy.. OncoImmunology, 2016, 5 (2), pp.e1082706. ⟨10.1080/2162402X.2015.1082706⟩. ⟨hal-01448304⟩
243 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More